- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.02. | RenovoRx, Inc.: RenovoRx Advancing RenovoCath Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum | 1 | GlobeNewswire (USA) | ||
| 10.02. | RenovoRx, Inc.: RenovoRx Establishes RenovoCath Medical Advisory Board | 1 | GlobeNewswire (USA) | ||
| RENOVORX Aktie jetzt für 0€ handeln | |||||
| 06.02. | RenovoRx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | RenovoRx, Inc.: RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer | 147 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and... ► Artikel lesen | |
| 04.02. | RenovoRx, Inc.: RenovoRx Announces Clinical Data Supporting the TAMP Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting | 1 | GlobeNewswire (USA) | ||
| 30.01. | Jones Trading stuft RenovoRx mit "Buy" ein - Kurspotenzial von über 700 % | 1 | Investing.com Deutsch | ||
| 30.01. | Jones Trading initiates coverage on RenovoRx stock with Buy rating | 2 | Investing.com | ||
| 28.01. | RenovoRx, Inc.: RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting | 2 | GlobeNewswire (USA) | ||
| 20.01. | RenovoRx, Inc.: RenovoRx Expands RenovoCath Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center | 1 | GlobeNewswire (USA) | ||
| 14.01. | RenovoRx, Inc.: RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026 | 5 | GlobeNewswire (USA) | ||
| 08.01. | RenovoRx, Inc.: RenovoRx To Announce Promising New Clinical Data Using its TAMP Therapy Platform in an Abstract to be Presented at ASCO GI 2026 | 1 | GlobeNewswire (USA) | ||
| 02.01. | RenovoRx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.11.25 | RenovoRx, Inc.: RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th | 1 | GlobeNewswire (USA) | ||
| 13.11.25 | RenovoRx, Inc.: RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update | 216 | GlobeNewswire (Europe) | September 30, 2025 Cash and Cash Equivalents at $10 million Revenue Expected to Grow in 2026 and Continue to Offset Cash Burn Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW... ► Artikel lesen | |
| 13.11.25 | RenovoRx, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | RenovoRx, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.25 | UCLA oncology surgeon joins RenovoRx's scientific advisory board | 1 | Investing.com | ||
| 06.11.25 | RenovoRx, Inc.: RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD | 1 | GlobeNewswire (USA) | ||
| 04.11.25 | RenovoRx, Inc.: RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th | 1 | GlobeNewswire (USA) | ||
| 09.10.25 | RenovoRx adds interventional oncology expert to scientific advisory board | 2 | Investing.com |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 70,35 | -19,83 % | Ihre wichtigsten Termine: Alle Blicke auf: Lindt & Sprüngli, Volkswagen, Renault, Biontech und Repsol | © Foto: © Volkswagen 2024Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00... ► Artikel lesen | |
| MODERNA | 46,640 | -2,36 % | Danaher, Moderna, Emyria: Drei Biotech-Aktien für die Beobachtungsliste im März 2026 | ||
| BIOGEN | 160,00 | 0,00 % | Biogen Inc.: The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome | -Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease-
-Data support... ► Artikel lesen | |
| ILLUMINA | 107,68 | +0,58 % | Illumina (ILMN) Gaining from Stronger Than Expected Results | ||
| CRISPR THERAPEUTICS | 49,000 | -2,97 % | CRISPR Therapeutics stock dips on $350M convertible debt offering | ||
| VIKING THERAPEUTICS | 29,000 | +0,16 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26
Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity... ► Artikel lesen | |
| ATAIBECKLEY | 3,160 | +1,94 % | AtaiBeckley Inc.: BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day | BPL-003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depressionCash runway reaffirmed through the planned early-2029 topline readouts... ► Artikel lesen | |
| TWIST BIOSCIENCE | 41,540 | -0,24 % | Twist Bioscience falls after over $2M insider sale | ||
| OCULAR THERAPEUTIX | 8,408 | -2,39 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| BIOXCEL THERAPEUTICS | 1,444 | -1,50 % | Why Are BioXcel Therapeutics Shares Down Friday? | ||
| BRIACELL THERAPEUTICS | 3,180 | -1,85 % | BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting | PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 14,310 | +3,32 % | Amylyx Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| HARMONY BIOSCIENCES | 28,535 | 0,00 % | UBS cuts Harmony Biosciences stock price target on earlier Wakix generic entry | ||
| VISTAGEN THERAPEUTICS | 0,611 | 0,00 % | VistaGen auf der TD Cowen Konferenz: Pherin-Plattform im Fokus | ||
| BARINTHUS BIOTHERAPEUTICS | 0,480 | +2,56 % | Barinthus Biotherapeutics: Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments | Single ascending dose data readout for VTP-1000 expected before the end of 2025Enrollment advancing in multiple ascending dose part of the AVALON trial; data expected in the second half of 2026Proposed... ► Artikel lesen |
RENOVORX INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,800 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RENOVORX INC finden Sie auf Wallstreet Online.